Celcuity Inc Announces $175M Convertible Notes and Common Stock Offering
ByAinvest
Thursday, Jul 31, 2025 2:09 pm ET1min read
CELC--
The convertible notes, with an interest rate of 2.750% annually, are senior unsecured obligations due 2031 and will be convertible at an initial rate of 19.4932 shares per $1,000 principal amount, equivalent to a conversion price of approximately $51.30 per share [1]. The common stock offering consists of 1,836,842 shares at $38.00 per share. The company expects to use the proceeds for working capital and general corporate purposes, including clinical trial expenditures, commercial launch preparations, research and development, and business development activities.
Celcuity's lead candidate, gedatolisib, is currently in Phase 3 clinical trials for HR+/HER2- advanced breast cancer and Phase 1/2 trials for metastatic castration-resistant prostate cancer. The company's recent Phase 3 VIKTORIA-1 clinical trial results showed promising outcomes, with the triplet therapy of gedatolisib, palbociclib, and fulvestrant significantly reducing the risk of disease progression or death by 76% compared to fulvestrant alone [2]. These results have bolstered investor confidence and led to a surge in the company's stock price.
The convertible notes offering is expected to close on August 1, while the common stock offering should close on July 31, subject to customary closing conditions. Jefferies, TD Cowen, and Leerink Partners are serving as joint book-running managers for both offerings, with LifeSci Capital acting as lead manager for the convertible notes offering and passive bookrunner for the common stock offering [1].
References:
[1] https://au.investing.com/news/company-news/celcuity-prices-175-million-convertible-notes-85-million-stock-offering-93CH-3949155
[2] https://ng.investing.com/news/company-news/celcuity-announces-225-million-in-proposed-public-offerings-93CH-2029312
Celcuity Inc (CELC) has priced a $175 million convertible notes offering and a common stock offering, raising approximately $248.7 million to support clinical trials and research and development. The convertible notes offer a 35% premium conversion price, reflecting investor confidence in the company's future growth. However, the lack of capped call transactions may introduce market volatility, and existing shareholders may experience potential dilution. The capital raised will be crucial for advancing oncology treatments.
Celcuity Inc. (NASDAQ: CELC) has priced a $175 million convertible notes offering and a common stock offering, raising approximately $248.7 million to support clinical trials and research and development. The convertible notes offer a 35% premium conversion price, reflecting investor confidence in the company's future growth. However, the lack of capped call transactions may introduce market volatility, and existing shareholders may experience potential dilution. The capital raised will be crucial for advancing oncology treatments.The convertible notes, with an interest rate of 2.750% annually, are senior unsecured obligations due 2031 and will be convertible at an initial rate of 19.4932 shares per $1,000 principal amount, equivalent to a conversion price of approximately $51.30 per share [1]. The common stock offering consists of 1,836,842 shares at $38.00 per share. The company expects to use the proceeds for working capital and general corporate purposes, including clinical trial expenditures, commercial launch preparations, research and development, and business development activities.
Celcuity's lead candidate, gedatolisib, is currently in Phase 3 clinical trials for HR+/HER2- advanced breast cancer and Phase 1/2 trials for metastatic castration-resistant prostate cancer. The company's recent Phase 3 VIKTORIA-1 clinical trial results showed promising outcomes, with the triplet therapy of gedatolisib, palbociclib, and fulvestrant significantly reducing the risk of disease progression or death by 76% compared to fulvestrant alone [2]. These results have bolstered investor confidence and led to a surge in the company's stock price.
The convertible notes offering is expected to close on August 1, while the common stock offering should close on July 31, subject to customary closing conditions. Jefferies, TD Cowen, and Leerink Partners are serving as joint book-running managers for both offerings, with LifeSci Capital acting as lead manager for the convertible notes offering and passive bookrunner for the common stock offering [1].
References:
[1] https://au.investing.com/news/company-news/celcuity-prices-175-million-convertible-notes-85-million-stock-offering-93CH-3949155
[2] https://ng.investing.com/news/company-news/celcuity-announces-225-million-in-proposed-public-offerings-93CH-2029312
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet